Literature DB >> 30573793

Setting dictates efficacy of pembrolizumab in TNBC.

Peter Sidaway1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30573793     DOI: 10.1038/s41571-018-0157-1

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  4 in total

1.  Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review.

Authors:  Gilbert Lazarus; Jessica Audrey; Anthony William Brian Iskandar
Journal:  Oncol Rev       Date:  2019-10-10

Review 2.  Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease.

Authors:  Camil Ciprian Mireștean; Constantin Volovăț; Roxana Irina Iancu; Dragoș Petru Teodor Iancu
Journal:  J Clin Med       Date:  2022-01-26       Impact factor: 4.241

Review 3.  Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies.

Authors:  Minru Liao; Rui Qin; Wei Huang; Hong-Ping Zhu; Fu Peng; Bo Han; Bo Liu
Journal:  J Hematol Oncol       Date:  2022-04-12       Impact factor: 17.388

Review 4.  Persistent EGFR/K-RAS/SIAH pathway activation drives chemo-resistance and early tumor relapse in triple-negative breast cancer.

Authors:  Amy H Tang; Richard A Hoefer; Mary L Guye; Harry D Bear
Journal:  Cancer Drug Resist       Date:  2022-06-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.